Alpha-GPC vs Citicoline: Compared by a Brand That Sells Neither

Why this comparison can stay neutral

Every ingredient brand writing this article has a checkout at the bottom of it. We do not: MAXXING sells no alpha-GPC, no citicoline, and no choline product of any kind, and this page is not teasing one. Nothing you read here routes to a cart, which is the only reason a no-winner verdict is even possible in this category.

One more disclosure, because it is the kind competitors skip. Our alpha-GPC facts come from the MAXXING alpha-GPC research library, 144 studies with every PMID checked against the National Library of Medicine. We have not built the same verified library for citicoline. So on this page, citicoline-only research is described generically, without study counts or figures we have not verified, while head-to-head trials that include both compounds are cited precisely. Pretending both columns are equally sourced is how comparison pages usually mislead; we would rather show you the seams.

What each molecule actually is

Alpha-GPC: choline on a glycerophosphate backbone

Alpha-GPC (L-alpha-glycerylphosphorylcholine, also sold as choline alfoscerate) is a choline molecule attached to a glycerophosphate backbone. It is water soluble, it occurs naturally in the body and in small amounts in food, and a large share of each gram is choline itself, one of the highest fractions of any common supplement form. Both compounds are studied as acetylcholine precursors, meaning research treats them as raw material the body can use toward the neurotransmitter acetylcholine.

Citicoline: choline plus cytidine, in one molecule

Citicoline (CDP-choline, cytidine diphosphate-choline, or the branded form Cognizin) is a two-part structure: choline linked to cytidine. Because cytidine occupies part of the molecule, a smaller share of each gram is choline than in alpha-GPC. Citicoline's research tradition treats the cytidine half as interesting in its own right, which is part of why the two compounds have separate literatures rather than one shared file.

We are deliberately not printing exact choline-by-weight percentages. Those figures circulate widely on supplement blogs, but they do not appear in our verified study library, and this page only prints numbers it can source. The qualitative picture is uncontested: gram for gram, alpha-GPC delivers more choline, and citicoline delivers choline plus cytidine.

The complete head-to-head record

Here is the part most comparison articles never say plainly: the entire randomized head-to-head record between these two compounds is three trials. A 2025 systematic review and meta-analysis pooled all three, 358 patients in total, and found alpha-GPC improved overall clinical condition on the SCAG scale more than citicoline, with no significant difference between the compounds on memory or word-fluency tests. Split decision, small numbers.

The earliest direct comparison is also worth reading in full. In a 1991 randomized multicentre trial, 120 patients with mild to moderate vascular dementia received injected alpha-GPC or citicoline at 1 g per day for 90 days; both groups improved on symptom measures and alpha-GPC scored statistically higher on most tests, but there was no placebo arm and no blinding. On the pharmacokinetic side, a 1992 randomized study in 12 healthy volunteers found a single 1,000 mg injected dose of alpha-GPC raised free plasma choline considerably higher than the same dose of citicoline, peaking within 15 to 30 minutes.

Now notice what the table does not contain: healthy adults taking oral supplements, which is who is actually reading this. The head-to-head trials were run in dementia-era clinical populations, during the decades when both compounds were prescription-style medicines in parts of Europe and Asia, and the two oldest used injections. Reporting a 1991 trial in vascular dementia patients is research history, not a promise about your focus at your desk.

What the wider evidence covers for each

Alpha-GPC, from our verified library

The 144-study library spans 1986 to 2026, with 65 human studies. The bulk of the human record is clinical: 30 studies sit in the clinical-cognition file, from the era when alpha-GPC was studied at 1,200 mg per day in patients with diagnosed conditions. Healthy adults are a much thinner file: a 32-person randomized trial from 1991 using a scopolamine challenge, a 39-person single-blind study from 2021 that logged higher self-reported motivation, and a 20-person randomized crossover from 2024 that measured cognitive-test scores after single doses. Athletic performance adds five small randomized trials of 12 to 48 participants each with mixed results, covered in our alpha-GPC pre-workout breakdown, plus two small acute growth-hormone studies.

Citicoline, described generically

Citicoline has its own large research tradition, including stroke-recovery trials, studies in age-related cognitive decline, attention research, and eye-health work. We are describing that literature generically, without counts or effect claims, because we have not verified it study by study the way we have for alpha-GPC. Treat that as a sourcing boundary, not a quality verdict in either direction.

The one pooled analysis that holds both

A 2023 systematic review of choline-containing phospholipids in stroke research, 15 studies and 8,357 subjects, is the largest analysis in our library containing both compounds. It reported that pooled citicoline trials showed no significant improvement in neurological function or functional recovery, while pooled alpha-GPC trials showed improvement on the scales used, and then it flagged its own asterisk: the alpha-GPC evidence came largely from open, uncontrolled trials. Both halves of that sentence deserve equal weight, and this is fact-reporting about a research literature, not treatment guidance. For the full picture of the compound, start at our alpha-GPC hub.

Choline bitartrate: the cheap third option

Choline bitartrate is choline bound to a tartrate salt: no phospholipid structure, no cytidine, usually the lowest price per gram of choline on the shelf, and the form most multivitamins and blends quietly use. Two facts from the verified library frame it fairly. First, in a 2022 randomized crossover in six healthy men, choline chloride, choline bitartrate, glycerophosphocholine, and egg phosphatidylcholine all raised plasma choline to a similar degree at matched choline doses, while every water-soluble form, glycerophosphocholine included, also raised TMAO, a gut-derived metabolite that cardiovascular researchers are still working out.

Second, the older clinical literature is less flattering: a 2001 review of cholinergic precursors reported that plain choline and lecithin failed in controlled dementia-era trials, while CDP-choline and alpha-GPC produced modest cognitive improvements in that clinical context. So bitartrate wins on plasma choline per dollar, while the phospholipid forms carry the clinical-trial history. Those are different questions, and a fair page keeps them separate.

Cost and form differences, qualitatively

We are not printing prices, because prices move and this page has no cart. The stable pattern: choline bitartrate is the commodity, usually cheapest per gram of choline; alpha-GPC sits mid-range; citicoline often positions at a premium, especially as the trademarked branded ingredient. One label trap is worth knowing for alpha-GPC specifically: the raw material readily absorbs moisture, so many powders are sold as 50% blends with a carrier. A scoop labeled 600 mg of 50% material contains 300 mg of actual alpha-GPC, which matters when you compare products, and our alpha-GPC dosage guide covers what amounts the studies themselves used.

The safety files, reported in both directions

Alpha-GPC has the most debated safety file in the choline category, and it comes down to two large Korean cohorts that point in opposite directions. In a 2021 national cohort of roughly 12 million adults aged 50 and over, prescription alpha-GPC users showed a 43 to 46% higher 10-year risk of stroke than matched non-users, rising with longer use, an observational finding with a confounding-by-indication caveat since users were prescribed it for cognitive complaints. In a 2025 cohort of 508,107 patients newly diagnosed with mild cognitive impairment, alpha-GPC users showed a lower risk of progressing to dementia and lower stroke risk among those who did not progress, also observational, also unable to prove causation. No page should show you one of those without the other; most show neither. The full breakdown lives in our alpha-GPC side effects guide.

Citicoline has its own separate tolerability literature, which we describe generically for the sourcing reason already stated. And one signal crosses all the water-soluble forms rather than favoring either side: in the 2022 crossover above, bitartrate, chloride, and glycerophosphocholine all raised TMAO. Whatever that turns out to mean, it is not a tiebreaker between these two.

Which fits which goal (no winner, on purpose)

The honest way to close a comparison with no winner is to hand you the right questions per goal:

• Focus or studying as a healthy adult. The head-to-head trials do not cover you. Alpha-GPC's healthy-adult file is three small trials; citicoline has its own healthy-adult research we describe only generically. Anyone declaring a winner for this goal is reading past the data, so the real question is which small, unreplicated evidence base you find more persuasive.
• Pre-workout use. The specific small-trial literature here belongs to alpha-GPC: five randomized trials, mixed results, none head-to-head against citicoline. The question is whether trials of 12 to 48 people are enough to justify a purchase.
• Covering dietary choline cheaply. Choline bitartrate delivered plasma choline comparably to glycerophosphocholine at matched doses in the 2022 crossover, at the lowest typical cost. The question is whether you need anything beyond plasma choline.
• Anything involving a diagnosed condition. The clinical trials behind both compounds were prescription-era medicine, not supplement-aisle decisions. That conversation belongs with your doctor, full stop, and the same goes if you take medications or are pregnant or nursing.

Frequently asked questions